Publication
Frameshift events predict anti-PD-1/L1 response in head and neck cancer.
Authors not recorded
JCI Insight2018PMID 29467336PMC5916245stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 10, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260910-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (3)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 3
- cancerHead and Neck Squamous Cell Carcinomacivic_curation1.00
- drugPD1 Inhibitorcivic_curation1.00
- variantHighcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-10
- Retrieved
- Sep 10, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29467336
- Run
- ING-CIVIC-20260910-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| High1 | ||||||||
| PD1 Inhibitor | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID13241This observational cohort study assessed the association between total mutational burden (TMB) and the efficacy of anti-PD-1/L1 therapy in head and neck squamous cell carcinoma. Using large comprehens… (full text at CIViC) PMID 29467336 · Hanna et al., 2018 · Open in CIViC | civic |